▲ Peaking
Business
🔮 fades
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
Bristol Myers Squibb reports Phase 2 success for its next-generation GPRC5D-directed CAR-T therapy targeting heavily pre-treated myeloma patients.